The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Biopharmaceutical Considerations In Topical Ocular Drug Delivery
Abstract
SUMMARY: 1. Despite the accessibility of the front of the eye, efficient delivery of drug to treat various ocular disorders is a challenge to the formulation scientist. The majority of ophthalmic medications are formulated as eye drops. Due to anatomical constraints, the volume that can be administered is limited to approximately 30 μL. This, together with the efficient clearance system that exists in the front of the eye, makes it difficult to maintain an effective pre‐ocular drug concentration for a desired length of time. Various formulation strategies have been used to increase pre‐ocular retention of eye drops. The most successful of these has been the inclusion of viscosity enhancing polymers, particularly those able to interact with the mucous layer on the eye surface or those that can undergo a transition from a solution to a gel under the conditions of the pre‐ocular area. 2. When the target site is intra‐ocular, drug must be absorbed from the pre‐ocular region into the eye. The main route for absorption is across the cornea. However, absorption of drug across the cornea is inefficient due to its impermeable nature and small surface area. Thus, the intra‐ocular bioavailability of topically administered medications is typically less than 10%. 3. Corneal permeability favours moderately lipophilic compounds. These compounds often have a low aqueous solubility. Problems in ocular drug delivery and formulation are compounded for poorly soluble drugs that must be formulated as suspensions. 4. Reformulation of ophthalmic suspensions as solutions has many advantages. This may be achieved by complexation using cyclodextrins. Solubilization using cyclodextrins can overcome many of the formulation problems. However, it is unclear as to their potential for improving ocular bioavailability, which is seemingly drug dependent and may be influenced by both the physicochemical properties of the drug and the complex formed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szejtli, J. (1988) · Topics in Inclusion Science · doi:10.1007/978-94-015-7797-7 · Cited by 1,759
Determination of tear volume and tear flow.
Mishima, S., Gasset, A. R., Klyce, S. D., & BAUM, J. L. (1966) · PubMed · Cited by 607
Lacrimal and Instilled Fluid Dynamics in Rabbit Eyes
Chrai, S. S., Patton, T. F., Mehta, A., & Robinson, J. R. (1973) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600620712 · Cited by 354
Mechanistic and Quantitative Evaluation of Precorneal Pilocarpine Disposition in Albino Rabbits
Lee, V. H.-L., & Robinson, J. R. (1979) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600680606 · Cited by 230
Comparison of conjunctival and corneal surface areas in rabbit and human
Watsky, M. A., Jablonski, M. M., & Edelhauser, H. F. (1988) · Current Eye Research · doi:10.3109/02713688809031801 · Cited by 192
Schoenwald, R. D., & Ward, R. L. (1978) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600670614 · Cited by 152
Wang, W., Sasaki, H., Chien, D., & Lee, V. H. L. (1991) · Current Eye Research · doi:10.3109/02713689109001766 · Cited by 142
Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption
Ahmed, I. I. K., & Patton, T. F. (1987) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(87)90092-5 · Cited by 119
Design and evaluation of controlled release systems for the eye
Gurny, R., Ibrahim, H., Aebi, A., Buri, P. A., Wilson, C. G., Washington, N., Edman, P., & Camber, O. (1987) · Journal of Controlled Release · doi:10.1016/0168-3659(87)90090-3 · Cited by 109
Usayapant, A., Karara, A. H., & Narurkar, M. M. (1991) · Pharmaceutical Research · doi:10.1023/a:1015838215268 · Cited by 77
Cited by
Vesicular systems in ocular drug delivery: an overview
Kaur, I. P., Garg, A., Singla, A. K., & Aggarwal, D. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.09.016 · Cited by 450
Nanoparticles for drug delivery to the anterior segment of the eye
Janagam, D. R., Wu, L., & Lowe, T. L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.001 · Cited by 341
Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery
Jiao, J. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.002 · Cited by 314
Gaballa, S. A., Kompella, U. B., Elgarhy, O., Alqahtani, A. M., Pierscionek, B., Alany, R. G., & Abdelkader, H. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00843-z · Cited by 255
Topical drug delivery systems: a patent review
Singh Malik, D., Mital, N., & Kaur, G. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1131267 · Cited by 192
Metadata
- Authors
- Davies, N. M.
- Venue
- Clinical and Experimental Pharmacology and Physiology
- Publisher
- Wiley
- Published
- 2000-07-17
- Volume
- 27
- Issue
- 7
- Pages
- 558-562
- ISSN
- 0305-1870 (ISSN-L)
- 1440-1681
- OpenAlex
- W2086475585
- Cited by
- 267
- References
- 12
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biopharmaceutical Considerations In Topical Ocular Drug Delivery. https://app.cochat.ai/papers/10.1046/j.1440-1681.2000.03288.x
- The paper
- Davies, N. M. (2000). Biopharmaceutical Considerations In Topical Ocular Drug Delivery. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1046/j.1440-1681.2000.03288.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.